- Home
- SKYE vs BDTX Comparison
SKYE vs BDTX Comparison
Compare SKYE & BDTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SKYE
- BDTX
- Stock Information
- Founded
- SKYE 2012
- BDTX 2014
- Country
- SKYE United States
- BDTX United States
- Employees
- SKYE N/A
- BDTX N/A
- Industry
- SKYE Biotechnology: Pharmaceutical Preparations
- BDTX Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- SKYE Health Care
- BDTX Health Care
- Exchange
- SKYE Nasdaq
- BDTX Nasdaq
- Market Cap
- SKYE 108.3M
- BDTX 323.2M
- IPO Year
- SKYE N/A
- BDTX 2020
- Fundamental
- Price
- SKYE $4.94
- BDTX $3.31
- Analyst Decision
- SKYE Buy
- BDTX Strong Buy
- Analyst Count
- SKYE 6
- BDTX 4
- Target Price
- SKYE $18.67
- BDTX $15.50
- AVG Volume (30 Days)
- SKYE 308.0K
- BDTX 932.5K
- Earning Date
- SKYE 11-09-2024
- BDTX 11-04-2024
- Dividend Yield
- SKYE N/A
- BDTX N/A
- EPS Growth
- SKYE N/A
- BDTX N/A
- EPS
- SKYE N/A
- BDTX N/A
- Revenue
- SKYE N/A
- BDTX N/A
- Revenue This Year
- SKYE N/A
- BDTX N/A
- Revenue Next Year
- SKYE N/A
- BDTX N/A
- P/E Ratio
- SKYE N/A
- BDTX N/A
- Revenue Growth
- SKYE N/A
- BDTX N/A
- 52 Week Low
- SKYE $1.44
- BDTX $1.62
- 52 Week High
- SKYE $19.41
- BDTX $7.66
- Technical
- Relative Strength Index (RSI)
- SKYE 58.26
- BDTX 33.12
- Support Level
- SKYE $4.01
- BDTX $3.13
- Resistance Level
- SKYE $5.48
- BDTX $3.42
- Average True Range (ATR)
- SKYE 0.46
- BDTX 0.24
- MACD
- SKYE 0.19
- BDTX 0.02
- Stochastic Oscillator
- SKYE 73.79
- BDTX 20.93
About SKYE Skye Bioscience Inc. Common Stock
Skye Bioscience Inc is a pre-clinical pharmaceutical company located in San Diego, California. The company's clinical assets focus on the modulation of cannabinoid receptor 1 ("CB1") to provide novel treatments and alternatives for diseases caused by metabolic disorders, inflammation, fibrosis and neurodegeneration, such as obesity and glaucoma. The company's Phase 2 clinical candidates include nimacimab, a negative allosteric modulating antibody that inhibits peripheral CB1 receptors, currently being developed for the treatment of obesity and SBI-100 Ophthalmic Emulsion ("SBI-100 OE"), a CB1 agonist (activator), currently being developed for the treatment of glaucoma and ocular hypertension.
About BDTX Black Diamond Therapeutics Inc.
Black Diamond Therapeutics Inc is a precision oncology medicine company. It is engaged in the discovery and development of small molecule, tumor-agnostic therapies. The company has one pipeline technology platform, namely Mutation-Allostery-Pharmacology, which is targeting mutations in cancer. Its drugs under the pipeline are BDTX-4933 and BDTX-1535.